Medical Cannabis

Our regulatory services include:

●Submission of Cannabis products in Europe:

In general and Germany in particular which is the most advanced among European countries. Generally, there is not a single route for Medical Cannabis approval across Europe thus, each EU country needs to be addressed according to its own regulations regarding Cannabis.

●Source of Product type:

 The source of the medicinal product may be synthetic or herbal;

1.A non-herbal source medicinal product route (e.g. synthetic origin) is a regular medicinal product route, manufactured in the pharmaceutical factories (such as paracetamol), and requires all tests to be approved (Clinical and Preclinical Trials).

2.Herbal-based medicinal product (similar to Sativex®): a medicinal product containing one or more active substances from a plant source or an herbal preparation or a combination of the two. Data should be presented that the herbal material has well-established pharmaceutical use, with over 15 years in the European community, a recognized efficacy and acceptable level of safety. In addition, it is necessary to demonstrate quality and consistency of the drug manufactured in order to ensure that the patient receives the same product every time and is free of contaminants. The competent authorities are entitled to request, where necessary, the data for: safety assessment, quality aspects of the medicinal product, the product must be analyzed for physical\chemical, biological and microbiological tests and to comply with the relevant quality standards in Europe: Pharmacopeial monograph, HPMC guidelines and relevant directives (2004/24 / EC & 2001/83 / EC).

●Obtaining a permit to import Medical Cannabis into Germany:

Germany only imports medical Cannabis from farms and facilities operating under the 1961 Convention of Narcotic Drugs. In order to import Medical Cannabis to Germany, an EU-GMP certificate from the EU member state is required. Manufacturers wishing to distribute Medical Cannabis products in Germany must be in agreement with, or be the owner of a domestic importer.

●Medical Cannabis Product Specifications:

Similarly, to medicinal products, test methods and specifications have been defined in some countries. The set

of methods and specifications for raw material or medicinal is defined as a monograph. In several countries where medical Cannabis products were approved, such as in the Netherlands and in Germany,

local monographs for medical Cannabis were defined.

●Facility associated regulatory aspects (e.g. the extent of required GMP in the post-harvest) :

The GMP requirements for Post-Harvest in Europe Medical cannabis manufacturers aiming to sell their products in Europe and specifically in the German market must meet two main requirements:

(1) compliance with the Herbal Medicinal Products Committee (HPMC) requirements of the European Medicines Agency (EMEA) and Good Agricultural and Collection Practice (GACP) Guidelines for Plant-Derived Starting Materials

(2) compliance with European GMP (EU-GMP) requirements, EudraLex – Volume 4 – Annex 7, Manufacture of Herbal Medicinal Products.

Annex 7 (to EU GMP) presents the requirements for facility, equipment, documentation and process control for production of herbal products.

Clinical studies are necessary for the development and approval of medical products.

Cannabis-based medical products require clinical trials and submission of detailed clinical study reports for registration/marketing authorization by the authorities. The study design is a key factor and must take into consideration the study population, intervention type, control group, response variables, measures to reduce bias, statistical analysis and so on. An appropriate clinical plan and trial execution will enable deep understanding of your product’s performance and its effect on humans.

Our clinical services include:

●Study planning and set up

●Study start up, documents preparation e.g. Clinical Protocol, Investigator Brochure, Informed Consent Form

●Study feasibility and sites selection

●Regulatory submissions and contracts

●Site management and clinical monitoring

●Data management and biostatistics

●Project management

●Interim and final study reports

There is no single uniform approach to design a preclinical program for all investigational products. Studies must be tailored according to the type of investigational product, and the proposed clinical trial in consideration of the respective guidelines or standards.

Our pre-clinical services include:

●Preclinical strategy planning

●Gap analysis

●In-vitro and in-vivo preclinical study design

●Prepare or review preclinical study protocols and reports

●Perform systematic literature review and interact with the regulatory authorities

●Assist in preclinical CRO selection

●Pre-Clinical CRO audit

●  Supporting the development of analytical and bio-analytical methods.